As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted options that may reshape ...

Patients with lupus face a high burden of comorbidities, with the presence of at least one of seven key conditions linked to 55%-60% lower odds of achieving remission or a low disease activity state.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...

Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

In a new study, krill oil concentrate (KOC) was found to safely reverse omega-3 deficiency in people with systemic lupus erythematosus (SLE) and decrease disease activity. A diet containing omega-3 ...

Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for treatment discontinuation and potential risk factors for subsequent ...

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.